The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
--------
Newbury Racecourse PLC - Newbury, England-based racing, entertainment and events company - In September, Newbury announced the launch of the Great Christmas Carnival at Newbury Racecourse in an agreement with Underbelly Ltd. Says the event was expected to create a new revenue stream, but now says event was not as well attended as expected, resulting in a material loss for both the company and Underbelly. Says its other core revenue streams during 2022 performed in line with its expectations and pre-Covid levels. Expects to ‘break even or make a small profit’ in 2022. Plans to announce 2022 results in May.
--------
Hydrogen Utopia International PLC - London-based developer of mixed plastic waste-to-fuel technology - Intends to withdraw its shares from trading on the AQSE Main Market. Under AQSE rules, the company is required to give 20 business days’ notice of its intention to withdraw from trading on AQSE. Expects trading to close on February 14.
--------
hVIVO PLC - London-based contract research organisation, formerly known as Open Orphan PLC - Consultancy services division Venn Life Sciences signs contract with a major global pharmaceutical client worth €3.2 million over two years. Contract begins in January 2023. The Venn division will provide clinical pharmacokinetics consultancy and programming services to the client. ‘Venn’s outstanding expertise and reputation in the industry over the past 25 years makes them a go-to partner. In addition, for infectious disease products, hVIVO and Venn have also been able to conduct projects from discovery to Phase II Challenge Studies, something no one else can offer,’ says Chief Executive Yamin Khan.
--------
Ecora Resources PLC - London-based natural resources royalty company - Says saleable production from Kestrel mine during the fourth quarter of 2022 was impacted by reduced mining rates and operational constraints that limited throughput volumes at the handling and preparation plant. Expects this to continue into 2023. The average price for product sold from its private royalty area during the period of around $280 per tonne was in line with the quarterly average market price, resulting in royalty income for quarter four of around $10 million. However, says strong pricing throughout 2022 resulted in a record Kestrel contribution of $107 million, versus $48 million in 2021. Plans to publish a full quarter four trading update on January 31.
--------
Image Scan Holdings PLC - Leicestershire, England-based X-ray screening systems supplier - Notes first sale of new product, with sale of two units of ThreatScan-AS1 Portable X-Ray system in Africa. Says customer is an African Explosive Ordnance Disposal unit, and the system has been supplied for use in counter EOD operations. Chief Executive Vincent Deery says: ‘Whilst we have been supplying our systems to EOD agencies all over the world for many years, this is the first sale of our recently released highest performing fully integrated system into the market.’
--------
Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says AVA6000 continues to show a ‘very favourable safety profile’ in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. AVA6000 is a form of the chemotherapy drug doxorubicin, which slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2.19 patients with a range of advanced and/or metastatic solid tumours enrolled across four cohorts, have been administered AVA6000 to date.
--------
N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Completes two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. ‘These studies are at an early stage in the development of an oral application, but show the versatility of Nuvec both in terms of its ease of formulation and application in a wide number of areas. Having successfully demonstrated Nuvec can be administered orally and locally transfect cells in the intestine, the next step is to investigate what the most suitable medical application might be for this delivery method,’ says Chief Executive Nigel Theobald.
--------
Dev Clever Holdings PLC - Software developer for immersive learning and career guidance - Cancels listing of its shares on London Stock Exchange. Says Tuesday is the last day of the company’s listing. Following cancellation, management will complete a rebranding of the company and its subsidiaries under the ‘Veative’ banner. Its name will change to Veative Group PLC.
--------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
